A similar mechanism was described in the context of systemic sclerosis wherein primary human skin fibroblasts treated with the VDR agonist paricalcitol, ligand-bound VDR associated with phosphorylated SMAD3 to inhibit downstream gene transcription [33]. This evidence concerns the gene VDR and systemic sclerosis.